Cover Image

A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients

The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET) is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in resistance to EGFR inhibitors. Emibetuzumab, a humanized immunoglobulin G4 monoclonal bivalent MET antibody, blocks ligand-dependent and l...

Full description

Saved in:
Bibliographic Details
Main Authors: Scagliotti, Giorgio V. (Author) , Moro-Sibilot, Denis (Author) , Kollmeier, Jens (Author) , Favaretto, Adolfo (Author) , Cho, Eun Kyung (Author) , Grosch, Heidrun (Author) , Kimmich, Martin (Author) , Girard, Nicolas (Author) , Tsai, Chun-Ming (Author) , Hsia, Te-Chun (Author) , Brighenti, Matteo (Author) , Schumann, Christian (Author) , Wang, Xuejing Aimee (Author) , Wijayawardana, Sameera R. (Author) , Gruver, Aaron M. (Author) , Wallin, Johan (Author) , Mansouri, Kambiz (Author) , Wacheck, Volker (Author) , Chang, Gee-Chen (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Journal of thoracic oncology
Year: 2019, Volume: 15, Issue: 1, Pages: 80-90
ISSN:1556-1380
DOI:10.1016/j.jtho.2019.10.003
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtho.2019.10.003
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S1556086419335300
Get full text
Author Notes:Giorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te-Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, Kambiz Mansouri, Volker Wacheck, Gee-Chen Chang

MARC

LEADER 00000caa a2200000 c 4500
001 1692280449
003 DE-627
005 20220818012010.0
007 cr uuu---uuuuu
008 200311r20202019xx |||||o 00| ||eng c
024 7 |a 10.1016/j.jtho.2019.10.003  |2 doi 
035 |a (DE-627)1692280449 
035 |a (DE-599)KXP1692280449 
035 |a (OCoLC)1341309976 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Scagliotti, Giorgio V.  |e VerfasserIn  |0 (DE-588)1077326319  |0 (DE-627)83633342X  |0 (DE-576)446219193  |4 aut 
245 1 2 |a A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients  |c Giorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te-Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, Kambiz Mansouri, Volker Wacheck, Gee-Chen Chang 
264 1 |c 2020 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Available online - 14 October 2019 
500 |a Gesehen am 11.03.2020 
520 |a The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET) is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in resistance to EGFR inhibitors. Emibetuzumab, a humanized immunoglobulin G4 monoclonal bivalent MET antibody, blocks ligand-dependent and ligand-independent hepatocyte growth factor/MET signaling. This phase 2 study compared erlotinib with and without emibetuzumab in first-line treatment of EGFR-mutant metastatic NSCLC. 
534 |c 2019 
650 4 |a Acquired resistance 
650 4 |a Antibody 
650 4 |a First-line mutation 
650 4 |a MET 
650 4 |a NSCLC 
700 1 |a Moro-Sibilot, Denis  |e VerfasserIn  |4 aut 
700 1 |a Kollmeier, Jens  |e VerfasserIn  |4 aut 
700 1 |a Favaretto, Adolfo  |e VerfasserIn  |4 aut 
700 1 |a Cho, Eun Kyung  |e VerfasserIn  |4 aut 
700 1 |a Grosch, Heidrun  |e VerfasserIn  |0 (DE-588)1122650159  |0 (DE-627)875958834  |0 (DE-576)481410198  |4 aut 
700 1 |a Kimmich, Martin  |e VerfasserIn  |4 aut 
700 1 |a Girard, Nicolas  |e VerfasserIn  |4 aut 
700 1 |a Tsai, Chun-Ming  |e VerfasserIn  |4 aut 
700 1 |a Hsia, Te-Chun  |e VerfasserIn  |4 aut 
700 1 |a Brighenti, Matteo  |e VerfasserIn  |4 aut 
700 1 |a Schumann, Christian  |e VerfasserIn  |4 aut 
700 1 |a Wang, Xuejing Aimee  |e VerfasserIn  |4 aut 
700 1 |a Wijayawardana, Sameera R.  |e VerfasserIn  |4 aut 
700 1 |a Gruver, Aaron M.  |e VerfasserIn  |4 aut 
700 1 |a Wallin, Johan  |e VerfasserIn  |4 aut 
700 1 |a Mansouri, Kambiz  |e VerfasserIn  |4 aut 
700 1 |a Wacheck, Volker  |e VerfasserIn  |4 aut 
700 1 |a Chang, Gee-Chen  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of thoracic oncology  |d Amsterdam : Elsevier, 2006  |g 15(2020), 1, Seite 80-90  |h Online-Ressource  |w (DE-627)508331986  |w (DE-600)2223437-8  |w (DE-576)336961553  |x 1556-1380  |7 nnas  |a A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients 
773 1 8 |g volume:15  |g year:2020  |g number:1  |g pages:80-90  |g extent:11  |a A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients 
856 4 0 |u https://doi.org/10.1016/j.jtho.2019.10.003  |x Resolving-System  |x Verlag  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S1556086419335300  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200311 
993 |a Article 
994 |a 2020 
998 |g 1122650159  |a Grosch, Heidrun  |m 1122650159:Grosch, Heidrun  |d 910000  |d 950000  |d 950900  |e 910000PG1122650159  |e 950000PG1122650159  |e 950900PG1122650159  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 6 
999 |a KXP-PPN1692280449  |e 3606519117 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"role":"aut","display":"Scagliotti, Giorgio V.","roleDisplay":"VerfasserIn","given":"Giorgio V.","family":"Scagliotti"},{"family":"Moro-Sibilot","given":"Denis","roleDisplay":"VerfasserIn","display":"Moro-Sibilot, Denis","role":"aut"},{"display":"Kollmeier, Jens","roleDisplay":"VerfasserIn","role":"aut","family":"Kollmeier","given":"Jens"},{"given":"Adolfo","family":"Favaretto","role":"aut","display":"Favaretto, Adolfo","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Cho, Eun Kyung","role":"aut","family":"Cho","given":"Eun Kyung"},{"family":"Grosch","given":"Heidrun","display":"Grosch, Heidrun","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Kimmich, Martin","roleDisplay":"VerfasserIn","role":"aut","family":"Kimmich","given":"Martin"},{"role":"aut","display":"Girard, Nicolas","roleDisplay":"VerfasserIn","given":"Nicolas","family":"Girard"},{"family":"Tsai","given":"Chun-Ming","roleDisplay":"VerfasserIn","display":"Tsai, Chun-Ming","role":"aut"},{"given":"Te-Chun","family":"Hsia","role":"aut","display":"Hsia, Te-Chun","roleDisplay":"VerfasserIn"},{"family":"Brighenti","given":"Matteo","roleDisplay":"VerfasserIn","display":"Brighenti, Matteo","role":"aut"},{"given":"Christian","family":"Schumann","role":"aut","roleDisplay":"VerfasserIn","display":"Schumann, Christian"},{"role":"aut","display":"Wang, Xuejing Aimee","roleDisplay":"VerfasserIn","given":"Xuejing Aimee","family":"Wang"},{"family":"Wijayawardana","given":"Sameera R.","roleDisplay":"VerfasserIn","display":"Wijayawardana, Sameera R.","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Gruver, Aaron M.","given":"Aaron M.","family":"Gruver"},{"family":"Wallin","given":"Johan","roleDisplay":"VerfasserIn","display":"Wallin, Johan","role":"aut"},{"role":"aut","display":"Mansouri, Kambiz","roleDisplay":"VerfasserIn","given":"Kambiz","family":"Mansouri"},{"role":"aut","display":"Wacheck, Volker","roleDisplay":"VerfasserIn","given":"Volker","family":"Wacheck"},{"given":"Gee-Chen","family":"Chang","role":"aut","roleDisplay":"VerfasserIn","display":"Chang, Gee-Chen"}],"title":[{"title_sort":"randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients","title":"A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients"}],"recId":"1692280449","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Available online - 14 October 2019","Gesehen am 11.03.2020"],"name":{"displayForm":["Giorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te-Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, Kambiz Mansouri, Volker Wacheck, Gee-Chen Chang"]},"id":{"eki":["1692280449"],"doi":["10.1016/j.jtho.2019.10.003"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"2020"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"Elsevier ; Lippincott Williams & Wilkins","dateIssuedKey":"2006","dateIssuedDisp":"2006-","publisherPlace":"Amsterdam ; Philadelphia, Pa."}],"id":{"issn":["1556-1380"],"eki":["508331986"],"zdb":["2223437-8"]},"pubHistory":["1.2006 -"],"part":{"pages":"80-90","issue":"1","year":"2020","extent":"11","text":"15(2020), 1, Seite 80-90","volume":"15"},"titleAlt":[{"title":"JTO"}],"disp":"A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patientsJournal of thoracic oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"recId":"508331986","title":[{"title_sort":"Journal of thoracic oncology","subtitle":"JTO ; official publication of the International Association for the Study of Lung Cancer","title":"Journal of thoracic oncology"}]}],"physDesc":[{"extent":"11 S."}]} 
SRT |a SCAGLIOTTIRANDOMIZED2020 

Similar Items